Determination of Arginine and Ascorbic acid in effervescent tablers by multidimensional chromatography

Andrea E. Rech\textsuperscript{a}; Cristina P. Farina\textsuperscript{b}, Pamela C. Lukasewicz Ferreira\textsuperscript{c} and Diogo Miron\textsuperscript{ad*}

\textsuperscript{a} School of Pharmacy, Health Science, Caxias do Sul University- UCS, Rua Francisco Getúlio Vargas, 1130. CEP 95070-560 - Caxias do Sul – RS, Brasil

\textsuperscript{b} Laboratório Farmacêutico Vitamed, Caxias do Sul, Rua Flávio Francisco Bellini, 459. CEP 95098-170 – Caxias do Sul – RS, Brasil.

\textsuperscript{c} Postgraduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Rio Grande do Sul. Av. Ipiranga, 2752 – Lab. 703. CEP 90610-000 - Porto Alegre – RS, Brasil.

\textsuperscript{d} School of Pharmacy, Federal University of Rio Grande do Sul.

Corresponding author e-mail: diogomiron@hotmail.com

This paper describes a fast and direct method for quantification of arginine and ascorbic acid (vitamin C) in effervescent tablets. HPLC-UV multidimensional chromatography (RP18 and cyanopropyl columns) was developed and validated. Phosphate buffer 10 mM p\textsubscript{H} 3.4 was used as mobile phase. Satisfactory resolution between the drugs was obtained with analysis time less than 8.0 min. Method was linear in the ranges of 140-320 \textmu g.mL\textsuperscript{-1} and 240-560 \textmu g.mL\textsuperscript{-1} for arginine and ascorbic acid, respectively. Precision showed RSD <2.0%. Recovery was 99.5% and 100.0% for arginine and ascorbic acid, respectively. Robustness was confirmed through factorial analysis \textsuperscript{2} (pH and mobile phase flow rate as factors).

Keywords: Arginine, Ascorbic Acid, HPLC-UV, Tandem Columns, Vitamin C.

Introduction

L-arginine is a basic and hydrophilic amino acid classified as a conditionally essential amino acid and in humans is synthesized from citrulline (1). Arginine (ARG) plays an important role in protein synthesis and increase muscle endurance by delaying the occurrence of peripheral fatigue. ARG is the immediate precursor of nitric oxide (NO), urea, ornithine and agmatine and is necessary for the synthesis of creatine. As a precursor of NO, arginine is used in many conditions where vasodilatation is required. It can also be used for the synthesis of polyamines (mainly through ornithine and to a lesser degree through agmatine, citrulline, and glutamate). Moreover, it is a precursor of proline and hydroxyproline, which are substances necessary for the synthesis of connective tissue (2,3).

Ascorbic acid (AA) is a water soluble vitamin essential to humans. It is part of a group of chemicals complex necessary for the proper functioning of the body and its deficiency may be caused by an unbalanced diet. AA is important in metabolic processes such as synthesis of collagen, so vital for the repair and healing of connective tissue (4), and synthesis of norepinephrine (5) and steroids (6). In addition, it acts on the immune system and also as an antioxidant neutralizing free radicals and oxidants (7).

Analysis of ARG by reverse phase (RP) HPLC is commonly carried out by pre-column derivatization. This process is commonly used to reduce ARG polarity, improving the interaction with the RP column, and also increases the wavelength of detection. Studies employing o-phthalaldehyde (8,9) and phenyl
isothiocyanate (10) for derivatization showed good results for analysis of ARG and metabolites. The sensitivity and selectivity of the mass detector were explored for the direct analysis of ARG and metabolites (11,12,13). Few studies are described with direct analysis of arginine by HPLC-UV detection. In this context can be cited the separation of arginine, ibuprofen and its impurities with detection at 264 nm (with bandwidth of 100 nm to achieve the detection of ARG at wavelength around 210 nm) (14). HPLC methods for AA employing electrochemical (15,16) and UV (17,18) detection are described for synthetic and biological samples.

Multidimensional chromatography employs two columns in sequence with different chromatographic selectivities. HPLC multidimensional methods are used to increase the resolution between substances in analysis of complex mixtures. Its advantageous is the direct analysis, in isocratic mode, of samples which commonly needed to be derivatized or require gradient system (19,20).

The combination of arginine and ascorbic acid in effervescent tablets is indicated for cicatrization, as antioxidant, to improve the immune system and in restrictive or inadequate diets, when there is vitamin C deficiency. In our searches, we have found no method for quantifying arginine and ascorbic acid in pharmaceutical formulations. The present work aims to develop and validate a direct and fast multidimensional HPLC-UV method for determination of ARG and AA in effervescent tablets.

**Experimental**

AA standard was purchased from MBN Chemicals Ltd.® with purity of 99.81% and arginine aspartate standard from Zhejiang Medicines and Health Products Imp. Ex® with purity of 99.23%. The concentration of arginine aspartate in the standard solutions was multiplied by the factor 0.567 to obtain the concentration of ARG. This factor was calculated by the ratio of ARG molecular weight (174.2 g.mol⁻¹) by arginine aspartate (307.3 g.mol⁻¹). Sodium phosphate dibasic anhydrous (Bold®), phosphoric acid (Vetec®) EDTA (Vetec®) and ultra-purified water from purification unit (RF Easypure®). Biofor C® effervescent tablets containing 1.0 g of ascorbic acid, 1.0 g of arginine aspartate and as inactive ingredients: citric acid, flavor solid with guarana açai, aspartame, sodium bicarbonate, colloidal silicon dioxide, colorant yellow, maltodextrin and mineral oil.

Chromatographic system consisted of a HPLC Merck Hitachi - Lachrom®, diode array detector and HSM software Multi-Manager®. Columns ACE® RP-18 (250 mm x 4 mm, 5 μm) and Spherisorb® cyanopropyl (250 mm x 4.6 mm, 5 μm). Sample filtration through Millex Millipore® membrane (nylon, 0.45 μm).

**Sample Preparation**

All samples (ARG and AA) were dissolved and diluted with sodium phosphate dibasic 10 mM adjusted to pH 3.4 with phosphoric acid and EDTA 0.005%, diluent solution. EDTA was added to chelate metal ions and minimize the degradation of ascorbic acid in solution. The volumetric flasks were protected from light with aluminum foil to prevent degradation of ascorbic acid.

The standard stock solutions (SSS) were prepared by weighing 50 mg of arginine aspartate, or 50 mg of AA in 25 mL volumetric flask, diluting to obtain concentrations of 1.15 and 2.00 mg.mL⁻¹ for arginine and ascorbic acid, respectively. From these SSS were made dilutions to obtain the concentrations for validation test.

**Analytical Method Development**

Variations in chromatographic conditions including composition (acetonitrile, methanol and aqueous phases), pH (2.5 – 7.0) and flow rate (0.6 – 1.2 mL.min⁻¹) of the mobile phase, and different columns (C18 and Cyanopropyl) were carried out to best fit the quantification of ARG and AA.
Validation Tests

The chromatographic conditions employed for the quantification of ARG and AA are described in Table 1. The validation process used the ICH guides as a reference (21).

Table 1. Chromatographic conditions for the quantification of arginine and ascorbic acid by multidimensional HPLC-UV.

<table>
<thead>
<tr>
<th>HPLC Variables</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobile Phase</td>
<td>10 mM phosphate buffer pH 3.4</td>
</tr>
<tr>
<td>Column Sequence</td>
<td>ACE® C18 (250 x 4 mm, 5 μm) and Spherisorb® cyanopropil - SCN (250 x 4.6 mm, 5 μm)</td>
</tr>
<tr>
<td>Injection Volume</td>
<td>20 μL</td>
</tr>
<tr>
<td>Flow rate</td>
<td>1.0 mL/min</td>
</tr>
<tr>
<td>Oven Temperature</td>
<td>30 °C</td>
</tr>
<tr>
<td>Detection</td>
<td>205 nm (bandwidth 8 nm)</td>
</tr>
<tr>
<td>Run time analysis</td>
<td>7.5 min</td>
</tr>
</tbody>
</table>

Specificity

Chromatograms from tablet samples (at concentration of 100%) were compared with placebo solution. Placebo solution was prepared by weighing a mixture of excipients of the effervescent tablets (anhydrous citric acid, baking soda, aspartame, maltodextrin, colloidal silicon dioxide, mineral oil, fragrance and dye) in volumetric flask of 25 mL using diluent as solvent. This solution was diluted to obtain placebo solution similar to those observed in the effervescent tablets.

For peak purity analysis, spectra in the range of 200–300 nm were recorded at a frequency of 0.5 Hz and noise set from 0.2 – 1.0 min. No detected impurity was considered when the peak purity index was greater than 0.995 and the threshold curve did not intercept the similarity curve.

Linearity

Linearity of the method was demonstrated through the construction of curves in the range of 60 – 140% (140-320 and 240-560 μg.mL⁻¹ for ARG and AA, respectively). For each curve were prepared five different concentrations (60, 80, 100, 120 and 140%), each one in triplicate in a total of 15 points (peak area vs concentration) per curve.

Precision

The method precision was evaluated by, repeatability and intermediate precision. Repeatability was determined by seven determinations at 100% of test concentration (230 and 400 μg.mL⁻¹ for ARG and AA, respectively) in duplicate. The test solutions were prepared from the triturated effervescent tablets which were weighted and diluted to working concentration. For each day of repeatability were prepared two standard solutions containing the drugs at a concentration of 100%. The intermediate precision was determined by analyzing the repeatability of the method on different days.

Accuracy

Solutions containing ARG and AA contaminated with placebo were prepared to access method accuracy. Five concentrations were used, covering the range of the test (60, 80, 100, 120 and 140%) for both drugs (ARG and AA). Each concentration was performed in duplicate. For calculation of recovery two standards containing only ARG and AA were prepared at 100% of test concentration.

Robustness

Robustness was evaluated by deliberate variations in pH and flow of mobile phase. The effect of factors (pH and flow) in the quantification of drugs and the chromatographic parameters (resolution, peak asymmetry, retention time and column efficiency) were evaluated by factorial design $2^2$. Flow rate levels tested were 0.90 and 1.05 mL.min⁻¹, and pH 3.2 and 3.6. Analysis on the nominal level of the method (pH 3.4 and flow
of 1.00 mL.min\(^{-1}\)) was performed to compare the results.

**Results and Discussion**

To obtain a chromatographic method for quantification of ARG and AA initially was tested reversed phase C18 columns (RP18), commonly used in drug analysis. ARG is positively charged (pKa = 13.2) across the pH range commonly used in HPLC (pH 2.0 – 8.5) which reduces the affinity of the drug by RP18 column. To increase the affinity of ARG was added sodium dodecyl sulfate (SDS 0.2%) on mobile phase as ion pair. This approach increase the retention time of ARG, but was not succeeded in separating the drugs under analysis (Figure 1.a).

**Figure 1.** Chromatograms of arginine (ARG) and ascorbic acid (AA) obtained during the method development. a) Phase reverse C18 (RP18) column using SDS as ion pair; b) Cyanopropyl column using pentane sulfonate as ion pair.

Due to the high polarity and water solubility of AA and ARG, were carried out assay with polar cyanopropyl column using phosphate buffer pH 3.4 as mobile phase. Pentane sulfonate (0.2%) was added to mobile phase, as ion pair, resulting in satisfactory resolution between the drugs and placebo (Figure 1.b). However, the diluent showed relevant signal at the same retention time of ARG. The influence of the diluent under these conditions was confirmed with peak purity value < 0.9 and high value of the intercept (8.5%) in a study of linearity with the ARG standard (Figure 2). The values of percentage intercept calculated by equation 1 must be lower than the specification established for precision (relative standard deviation - RSD < 2.0%, in this case), demonstrating that the method variation/error explain the intercept dimension obtained in the linearity test (22).

\[
\%\text{Intercept} = \frac{a}{b \times \bar{X}} \quad \text{Equation 1}
\]

Where \(a\) is the intercept; \(b\) is the slope; \(\bar{X}\) is the mean concentration.

**Figure 2.** Linearity plot of arginine using different columns (CN - cyanopropyl column, and multidimensional chromatography – RP18 + cyanopropyl columns in sequence). In bold the results of intercept percentage calculated by equation 1. CN data were normalized dividing it by the sum of multidimensional chromatography area.

Satisfactory results for the resolution of the drugs peaks, placebo and diluent were obtained using the columns RP18 and cyanopropyl in sequence (multidimensional chromatography) (Figure 3). Using this method there was no need of adding substances to ion pairing. Under these conditions it was possible to validate the method for quantification of ARG and AA as demonstrated by the results and discussions described below.

**Specificity**

In general, the use of wavelengths below 210 nm is avoided, basically for two reasons: the
emission of the deuterium lamp is lower in this band (signal/noise ratio is high and sensitivity low) and many interferers absorb in this region (potential specificity problem). At 205 nm ARG and AA (maximum and minimum wavelength, respectively) have similar absorptivities. As the working concentrations were not close to the limit of quantification and the placebo did not interfere with the analysis (as will prove the results of validation), the wavelength of 205 nm was selected for the ARG and AA quantifications.

There was no peak detected for placebo at the retention time corresponding to the chromatographic peaks of ARG and AA (Figure 3). Peak purity analysis does not detected impurities on the peaks of ARG and AA and the peak purity index was higher than 0.999 for both drugs. Retention times of ARG and AA were 6.30 and 6.95 min, respectively. The inversion in the order of elution of the drugs in the multidimensional chromatography method with respect to the methods of Figure 1 can be justified by the absence of ionic pair agent that alters the interaction of drugs with the columns.

**Figure 3.** Chromatograms of the Biofor C effervescent tablets and placebo at 205 nm with the columns RP-18 and cyanopropyl in sequence (multidimensional chromatography). Concentrations of 230 and 400 μg.mL\(^{-1}\) for arginine (ARG) and ascorbic acid (AA), respectively.

**Linearity**

The linear regression lines were obtained plotting the peak area at 205 nm (in mAu.s) versus the concentration of ARG or AA (in μg.mL\(^{-1}\)). The summary of results are in Table 2. The higher slope obtained with the results of AA compared to ARG shows a greater sensitivity of the method for detection of AA. The coefficients of determination (\(r^2\)) close to 1.00 show that virtually all the variation on the peak areas can be explained by variations in the concentrations of the drugs. The standardized residuals in the range of -2.0 to 2.0 shows that there were no outliers for peak area in the experimental data. Residual graphics showed normal distribution of results without the presence of trends, demonstrating that the model of first order, without transformation of data, is adequate to describe the relationship between peak area and concentration of the drugs. The ratio of the standard error of regression (SER) and the mean peak area obtained by the linear regression equation can be considered a measure of dispersion of the results of linearity (Equation 2), and comparable to the calculated RSD of the precision results. The low values of RSD\(_{\text{reg}}\) show that the method has adequate precision and were compatible with the technique and sample (tablets) analyzed (22).

\[
\text{RSD}_{\text{reg}} = \frac{\text{SER}}{b \times \bar{X}} \times 100\% \quad \text{Equation 2}
\]

Where: RSD\(_{\text{reg}}\) = relative standard deviation of the regression in %; SER = standard error of regression, \(b\) = the regression slope, \(\bar{X}\) = average concentration of the samples in the calibration curve.

<table>
<thead>
<tr>
<th>Linearity</th>
<th>Arginine</th>
<th>Ascorbic Acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration Range (μg/mL)</td>
<td>140 - 320</td>
<td>240 - 560</td>
</tr>
<tr>
<td>Equation</td>
<td>(y = 7251x + 33304)</td>
<td>(y = 10903x + 83049)</td>
</tr>
<tr>
<td>Determination Coefficient ((r^2))</td>
<td>0.9993</td>
<td>0.9998</td>
</tr>
<tr>
<td>Standadized Residuals (Extreme Values)</td>
<td>-1.44 , +1.33</td>
<td>-1.20 , +1.13</td>
</tr>
<tr>
<td>Residuals Plot</td>
<td>No tendency</td>
<td>No tendency</td>
</tr>
<tr>
<td>Regression Precision</td>
<td>1.0%</td>
<td>0.5%</td>
</tr>
<tr>
<td>Percentage Intercept</td>
<td>2.0%</td>
<td>1.8%</td>
</tr>
</tbody>
</table>
Precision

There is additive variance between the levels of precision and the highest variability is expected for the intermediate precision which includes the variations of system precision and repeatability. For samples at the same level of concentration is possible to calculate the system precision, from injections in duplicate, using Equation 3 (23).

\[
RSD_{Inj} = \sqrt{\frac{\sum (x_{i1} - x_{i2})^2}{2k}} \times 100\%
\]

Where: \(RSD_{Inj}\) is the HPLC system precision, in %; \(x_{i1}\) and \(x_{i2}\) are the peak areas of different injections of the sample \(i\); \(k\) is the number of samples; \(\bar{x}\) is the average peak area of the samples.

Repeatability was evaluated by calculating the RSD (RSD_{Rep}) from the results of different samples in each day of precision assay. The intermediate precision was obtained by measuring the variability (RSD_{Int}) of pooled results from different days of precision. Table 3 summarizes the results. Low values of RSD (< 2.0%) evaluated at all levels show that the method is precise.

During the precision assay has been verified that the sample solutions containing the drugs were stable for at least 12 h.

Accuracy

Recoveries of the drugs in the samples contaminated with placebo were 99.5% and 100.0% for ARG and AA, respectively. Variability of results was low with values of RSD for the ten samples, equal to 1.82% and 1.11% for ARG and AA, respectively. These results confirm the specificity, accuracy and precision of the analytical method proposed.

Robustness

An analytical method for use in routine should be able to withstand small variations without changing significantly the quantification of drugs. The proposed method is robust to variations on the factors pH and flow showing low variability (Table 4).

The transfer of analytical methods between laboratories often requires adaptations to adjust the chromatographic parameters (resolution, asymmetry, retention time). Thus, the analysis of the results of deliberate variations in method indicates that the pH 3.6 improves the resolution between peaks; the retention time increases with pH 3.2; the asymmetry of the peak of ARG is better at pH 3.2, while AA is at pH 3.6. The analysis with similar columns under the same conditions that was proposed in this study showed low resolution between ARG and AA. This problem was easily solved by reducing the flow to 0.8 mL.min\(^{-1}\) and increasing pH to 3.6.

| Table 3. Summary of results from different levels of precision for effervescent tablets. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Arginine        | Ascorbic acid   |
| Precision                        | Day 1           | Day 2           | Day 1           | Day 2           |
| Injection precision - RSD\(_{Inj}\) (%) | 0.41            | 0.54            | 0.43            | 0.36            |
| Repeatability - RSD\(_{Rep}\) (%)  | 1.64            | 1.41            | 1.04            | 1.12            |
| Intermediate precision – RSD\(_{Int}\) (%) and (Dose) | 1.57 (102.4%)   | 1.37 (97.0%)   |

| Table 4 Summary of robustness results. |
|---------------------------------|-----------------|-----------------|-----------------|
| Chromatographic conditions      | Arginine        | Ascorbic acid   |
|---------------------------------|-----------------|-----------------|-----------------|
| pH (Flow (mL.min\(^{-1}\))     | Data (%)        | Asymmetry | RT (min) | N | Retention | Data (%)        | Asymmetry | RT (min) | N | Retention |
|---------------------------------|-----------------|-----------------|-----------------|
| 3.4                             | 1.00            | 102.8%          | 1.08            | 0.91 | 1622     | 7.02             | 80.7%       | 0.87   | 1622     |
| 3.2                             | 0.80            | 101.4%          | 1.08            | 0.99 | 1625     | 7.03             | 80.6%       | 0.87   | 1625     |
| 3.2                             | 1.05            | 102.2%          | 1.25            | 1.14 | 2182     | 7.03             | 80.5%       | 0.87   | 2182     |
| 3.6                             | 0.80            | 103.8%          | 1.13            | 0.95 | 2091     | 4.42             | 84.9%       | 0.90   | 2091     |
| 3.6                             | 1.05            | 103.6%          | 1.23            | 1.04 | 1932     | 4.43             | 84.2%       | 0.90   | 1932     |
| Mean                            | 102.1%          | 10.0%           |                 |                 |                     |                 |                 |         |
| RSD                             | 0.41            | 0.43            |                 |                 |                     |                 |                 |         |

\(N\) = theoretical plates; \(RT\) = retention time between arginine and ascorbic acid peaks.
Conclusions

The use of multidimensional chromatography was effective to separate and quantify ARG and AA from effervescent tablets and there is no need for pre-column derivatization. The intercept from linear regression was able to detect a quantitative influence of the diluent in the analysis of ARG during the development phase of the HPLC method leading us to the use of multidimensional chromatography. Satisfactory results for specificity, linearity, precision, accuracy and robustness validate the method for analysis of effervescent tablets containing ARG and AA by multidimensional HPLC-UV.

Acknowledgements

The authors would like to thank Vitamed Laboratory for kindly supplying chromatographic columns and reference materials.

Conflict of Interest

The authors declare no conflicts of interest.

References


